AI Article Synopsis

  • A systematic review was conducted to explore the relationship between clinical and biological features and the effectiveness of two diabetes treatments: SGLT2-inhibitors and GLP1-receptor agonists, focusing on outcomes like glycaemic control, cardiovascular health, and kidney function.
  • Out of over 5,600 studies screened, only 101 for SGLT2-inhibitors and 75 for GLP1-receptor agonists were included, but many had methodological flaws that limited their reliability in assessing how different patients react to these treatments.
  • Findings suggest that factors like lower kidney function and reduced insulin secretion could affect treatment responses, but overall evidence is weak; further well-designed studies are needed to better understand treatment diversity and enhance

Article Abstract

Background: A precision medicine approach in type 2 diabetes requires the identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity could support more individualized clinical decisions on optimal type 2 diabetes therapy.

Methods: We performed a pre-registered systematic review of meta-analysis studies, randomized control trials, and observational studies evaluating clinical and biological features associated with heterogenous treatment effects for SGLT2-inhibitor and GLP1-receptor agonist therapies, considering glycaemic, cardiovascular, and renal outcomes. After screening 5,686 studies, we included 101 studies of SGLT2-inhibitors and 75 studies of GLP1-receptor agonists in the final systematic review.

Results: Here we show that the majority of included papers have methodological limitations precluding robust assessment of treatment effect heterogeneity. For SGLT2-inhibitors, multiple observational studies suggest lower renal function as a predictor of lesser glycaemic response, while markers of reduced insulin secretion predict lesser glycaemic response with GLP1-receptor agonists. For both therapies, multiple post-hoc analyses of randomized control trials (including trial meta-analysis) identify minimal clinically relevant treatment effect heterogeneity for cardiovascular and renal outcomes.

Conclusions: Current evidence on treatment effect heterogeneity for SGLT2-inhibitor and GLP1-receptor agonist therapies is limited, likely reflecting the methodological limitations of published studies. Robust and appropriately powered studies are required to understand type 2 diabetes treatment effect heterogeneity and evaluate the potential for precision medicine to inform future clinical care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551026PMC
http://dx.doi.org/10.1038/s43856-023-00359-wDOI Listing

Publication Analysis

Top Keywords

treatment heterogeneity
24
type diabetes
16
glp1-receptor agonists
12
treatment
8
diabetes treatment
8
systematic review
8
precision medicine
8
clinical biological
8
biological features
8
evidence treatment
8

Similar Publications

Pharmacogenomics stands as a pivotal driver toward personalized medicine, aiming to optimize drug efficacy while minimizing adverse effects by uncovering the impact of genetic variations on inter-individual outcome variability. Despite its promise, the intricate landscape of drug metabolism introduces complexity, where the correlation between drug response and genes can be shaped by numerous nongenetic factors, often exhibiting heterogeneity across diverse subpopulations. This challenge is particularly pronounced in datasets such as the International Warfarin Pharmacogenetic Consortium (IWPC), which encompasses diverse patient information from multiple nations.

View Article and Find Full Text PDF

Objective: Tuberous sclerosis complex (TSC) is a monogenetic disorder associated with sustained mechanistic target of rapamycin (mTOR) activation, leading to heterogeneous clinical manifestations. Epilepsy and renal angiomyolipoma are the most important causes of morbidity in adult people with TSC (pwTSC). mTOR is a key player in inflammation, which in turn could influence TSC-related clinical manifestations.

View Article and Find Full Text PDF

Aim: Self-inflicted oral-dental mutilations (SIODMs) are the result of an intentional or unintentional action that leads to anatomical and functional damage to the soft and hard tissues of the oral cavity. In paediatric patients they can be associated with both organic and functional diseases. A systematic review was conducted aiming to consolidate and integrate the existing knowledge on SIODM in paediatric patients.

View Article and Find Full Text PDF

Background: Calf muscle weakness is a common symptom in slowly progressive neuromuscular disorders that lead to walking problems like instability and increased walking effort. The mainstay of treatment to improve walking in this population is the provision of ankle-foot-orthoses (AFOs). Since we are not aware of an up-to-date and complete overview of the effects of AFOs used for calf muscle weakness in slowly progressive neuromuscular disorders, we reviewed the evidence for the effectiveness of AFOs to improve walking in this patient group, in order to support clinical decision-making.

View Article and Find Full Text PDF

Mathematical models of viral dynamics are crucial in understanding infection trajectories. However, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load data often includes limited sparse observations with significant heterogeneity. This study aims to: (1) understand the impact of patient characteristics in shaping the temporal viral load trajectory and (2) establish a data collection protocol (DCP) to reliably reconstruct individual viral load trajectories.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!